Nyxoah is currently a clinical-stage and commercial-ramp medical technology company that operates at a net loss as it heavily reinvests capital into research and development, clinical trials, regulatory compliance, and worldwide market expansion. While revenue generation continues to scale upward with commercial adoption in Europe and the United States, achieving sustained net profitability remains a longer-term financial milestone tied to broader sales volume growth.